Italian Drugmaker Making Great Strides On Mesothelioma Treatment
There is new hope on the horizon for people around the world suffering from an asbestos-related disease known as malignant pleural mesothelioma, as well as patients currently suffering from other forms of rare cancers. The Italian drug manufacturer, MolMed S.p.A., has been conducting research on an orphan drug designated by the FDA to treat Mesothelioma. An orphan drug is a medication designed for treating various rare medical conditions. The company is currently enrolling patients for Phase II of clinical trials for further studies pertaining to soft tissue sarcomas. When exposed to asbestos, individuals inhale tiny fibers, which become trapped in the lung lining, and form irritations, infections, and a specific type of cancer referred to as malignant pleural mesothelioma. Approximately 3,000 people in the U.S. receive a diagnosis of mesothelioma annually, with that number expected to grow exponentially over the next 20 years. As the disease mimics other conditions, afflicted persons often experience difficulty in receiving proper diagnosis and treatment. Considered a vascular targeting agent, the medication known as NGR-hTNF locates tumor cells within the body and inhibits blood vessel formation. The latest clinical trial study focuses on the medication’s ability to treat specific soft tissue sarcomas, when used alone and in combination with doxorubicin. The treatment carries the classification of being a peptide/cytokine complex, due to the combination of NGR (peptide) and TNF (cytokine). In addition to testing combined treatments of NFG-TNF with doxorubin, the medication is also in testing stages with other forms of therapy to treat mesothelioma and other cancers. MolMed S.p.A. is also conducting Phase III clinical research of NFG-hTNF and the medication’s ability to combat malignant pleural mesothelioma. The medication produced impressive results in Phase II against colorectal cancer, mesothelioma and liver cancer. Researchers are also testing the orphan drug’s ability to fight small cell lung and ovarian cancers. Higher doses of the medication have shown promise with respect to treating certain tumors in the arms and legs. The U.S. and the European Union, consider NGR-hTNF an orphan drug for treating mesothelioma and liver cancer. MolMed’s CEO, Claudio Bordignon, recently announced the results of the latest clinical study. The exciting conclusions were presented at an annual meeting of the European Society of Medical Oncology in Milan.